# **Contents**

| Foreword                                   | mer 112 18                | ix   |
|--|---------------------------|------|
| Acknowledgements                           | most process              | X    |
| List of background papers and contributors | TAL STRUCT                | XV   |
| Abbreviations                              |                           | XVII |
|  | and the same              |      |
| Chapter 1. Introduction                    |                           |      |
| Structure of the report                    |                           | 1    |
| Psychoactive substances and their socie    | olegal status             | 1    |
| Global use of psychoactive substances      |                           | ., 4 |
| Tobacco                                    |                           | 4    |
| Alcohol                                    |                           | 5    |
| Illicit use of controlled substances       |                           | 9    |
| Adverse effects of psychoactive substan    | nces and their mechanisms |      |
| of action                                  |                           | 10   |
| Substance dependence in relation to ne     | uroscience                | 12   |
| The burden of harm to health from psyc     |                           | 16   |
|  |                           |      |
| Chapter 2. Brain Mechanisms: Neurobi       | ology and Neuroanatom     | v 19 |
| Introduction                               | ology and recuroanatom    | 19   |
| Organization of the brain                  |                           | 19   |
| The neuron                                 |                           | 25   |
| Cell body                                  |                           | 26   |
| Dendrites                                  |                           | 26   |
| Axon                                       |                           | 28   |
| Terminal buttons                           |                           | 28   |
| Neurotransmission                          |                           | 29   |
| Action potential                           |                           | 29   |
| Neurotransmitter release                   |                           | 30   |
| Receptors                                  |                           | 31   |
| Neurotransmitters                          |                           | 32   |
| Acetylcholine                              |                           | 33   |
| γ-aminobutyric acid                        |                           | 33   |
| Glutamate                                  |                           | 33   |
| Dopamine                                   |                           | 34   |
| Norepinephrine                             |                           | 34   |
|  |                           |      |

## NEUROSCIENCE OF PSYCHOACTIVE SUBSTANCE USE AND DEPENDENCE

| Serotonin   | 35        |
|---|-----------|
| Peptides  | 35        |
| Genes   | 35        |
| Cellular and neuronal effects of psychoactive substances  | 36        |
| Cellular effects  | 36        |
| Neuronal effects  | 38        |
| Conclusion  | 39        |
| Chapter 3. Biobehavioural Processes Underlying Dependence | 43        |
| Introduction  | 43        |
| Defining terms  | 44        |
| Classical or Pavlovian conditioning                       | 44        |
| Instrumental or operant conditioning                      | 46        |
| Reinforcer  | 47        |
| Reward  | 47        |
| Incentive   | 47        |
| Motivation  | 48        |
| Incentive-motivational responding                         | 48        |
| Drug reward alone does not explain drug dependence        | 48        |
| Drug dependence as a response to incentive-motivation     | 49        |
| Drug dependence as a response to drug withdrawal          | 50        |
| Dopamine and reinforcement learning                       | 50        |
| Dependence-producing drugs as surrogates of conventional  | m 4       |
| reinforcers   | 51        |
| Dopamine and incentive sensitization                      | 52        |
| Psychomotor sensitization                                 | 53        |
| Sensitization and drug reward                             | 53        |
| Sensitization and tolerance                               | 54        |
| Individual differences                                    | 55<br>= 0 |
| Summary   | 58        |
| Chapter 4. Psychopharmacology of Dependence for Different |           |
| Drug Classes  | 67        |
| Introduction  | 67        |
| Alcohol (ethanol)   | 69        |
| Introduction  | 69        |
| Behavioural effects                                       | 69        |
| Mechanism of action                                       | 70        |
| Tolerance and withdrawal                                  | 70        |
| Neurobiological adaptations to prolonged use              | 72        |
| Pharmacological treatment of alcohol dependence           | 72<br>73  |
| Sedatives and hypnotics Introduction                      | 73<br>73  |
| Behavioural effects                                       | 73<br>73  |
| Mechanism of action                                       | 73<br>74  |
| modulation of action                                      | / 7       |

## CONTENTS

| Tolerance and withdrawal                         | 74  |
|--|-----|
| Neurobiological adaptations to prolonged use     | 75  |
| Tobacco  | 75  |
| Introduction                                     | 75  |
| Behavioural effects                              | 75  |
| Mechanism of action                              | 76  |
| Tolerance and withdrawal                         | 77  |
| Pharmacological treatment of nicotine dependence | 78  |
| Opioids  | 79  |
| Introduction                                     | 79  |
| Behavioural effects                              | 79  |
| Mechanism of action                              | 80  |
| Tolerance and withdrawal                         | 80  |
| Neurobiological adaptations to prolonged use     | 81  |
| Pharmacological treatment of opioid dependence   | 81  |
| Cannabinoids                                     | 84  |
| Introduction                                     | 84  |
| Behavioural effects                              | 85  |
| Mechanism of action                              | 86  |
| Tolerance and withdrawal                         | 87  |
| Neurobiological adaptations to prolonged use     | 88  |
| Cocaine (hydrochloride and crack)                | 89  |
| Introduction                                     | 89  |
| Behavioural effects                              | 89  |
| Mechanism of action                              | 89  |
| Tolerance and withdrawal                         | 91  |
| Neurobiological adaptations to prolonged use     | 91  |
| Pharmacological treatment of cocaine dependence  | 92  |
| Amphetamines                                     | 93  |
| Introduction                                     | 93  |
| Behavioural effects                              | 94  |
| Mechanism of action                              | 95  |
| Tolerance and withdrawal                         | 95  |
| Neurobiological adaptations to prolonged use     | 96  |
| Ecstasy  | 96  |
| Introduction                                     | 96  |
| Behavioural effects                              | 99  |
| Mechanism of action                              | 99  |
| Tolerance and withdrawal                         | 100 |
| Neurobiological adaptations to prolonged use     | 100 |
| Volatile solvents                                | 100 |
| Introduction                                     | 100 |
| Behavioural effects                              | 101 |
| Mechanism of action                              | 102 |

## NEUROSCIENCE OF PSYCHOACTIVE SUBSTANCE USE AND DEPENDENCE

| Tolerance and withdrawal   | 103 |
|--|-----|
| Neurobiological adaptations to prolonged use                     | 103 |
| Hallucinogens  | 104 |
| Introduction   | 104 |
| Behavioural effects  | 105 |
| Mechanism of action  | 105 |
| Tolerance and withdrawal   | 105 |
| Neurobiological adaptations to prolonged use                     | 106 |
| Summary  | 106 |
| Chapter 5. Genetic Basis of Substance Dependence                 | 125 |
| Introduction   | 125 |
| Family, twin and adoption studies: estimations of heritability   | 127 |
| Identifying chromosomal locations of interest: linkage studies   | 127 |
| Candidate gene approach  | 128 |
| Animal studies   | 128 |
| Genetics of tobacco dependence                                   | 130 |
| Heritability of tobacco dependence                               | 130 |
| Tobacco dependence and linkage studies                           | 131 |
| Candidate genes for tobacco dependence                           | 131 |
| Genetics of alcohol dependence                                   | 132 |
| Heritability of alcohol dependence                               | 132 |
| Alcohol dependence and linkage studies                           | 133 |
| Candidate genes for alcohol dependence                           | 134 |
| Genetics of opioid dependence                                    | 136 |
| Heritability of opioid dependence                                | 136 |
| Opioid dependence and linkage studies                            | 136 |
| Candidate genes for opioid dependence                            | 136 |
| Genetics of the combined risk of dependence on tobacco, alcohol, |     |
| opioids and other psychoactive substances                        | 138 |
| Heritability of substance dependence                             | 138 |
| Linkage studies of substance dependence                          | 139 |
| Candidate genes involved in substance dependence                 | 140 |
| Confounding issues in linkage and candidate gene studies         | 147 |
| Environment  | 147 |
| Genetice heterogeneity   | 147 |
| Phenotype  | 148 |
| Comorbidity  | 148 |
| Methodological issues  | 148 |
| Future directions  | 149 |
| Social and cultural aspects                                      | 150 |
| Risk factors and protective factors for dependence: an overview  | 150 |
| Summary  | 151 |

## CONTENTS

| Chapter 6. Concurrent Disorders                                    | 169 |
|--|-----|
| Introduction   | 169 |
| Hypotheses that may explain the observed comorbidity               | 170 |
| Schizophrenia  | 171 |
| Tobacco smoking and schizophrenia                                  | 171 |
| Psychostimulant (cocaine and amphetamine) dependence and           |     |
| schizophrenia  | 174 |
| Alcohol use and schizophrenia                                      | 176 |
| Neurobiological interactions between schizophrenia and the effects |     |
| of psychoactive substances   | 176 |
| Depression   | 180 |
| Tobacco smoking and depression                                     | 181 |
| Psychostimulant dependence and depression                          | 182 |
| Alcohol use and depression   | 183 |
| Neurobiological interactions between depression and the effects    |     |
| of psychoactive substances   | 184 |
| Discussion and conclusions   | 188 |
| Chapter 7. Ethical Issues in Neuroscience Research on Substance    |     |
| Dependence Treatment and Prevention                                | 209 |
| Introduction   | 209 |
| Types of research on neuroscience of substance dependence          | 209 |
| Animal experiments   | 209 |
| Epidemiological research on substance dependence                   | 209 |
| Experimental studies in humans                                     | 210 |
| Clinical trials of pharmacotherapy for substance dependence        | 210 |
| Trials of pharmacotherapies to prevent substance dependence        | 211 |
| Approach to ethical analysis                                       | 211 |
| Principles of biomedical ethics                                    | 216 |
| Human rights   | 217 |
| Ethics of animal experimentation in neuroscience research          | 218 |
| Ethical principles in human biomedical research                    | 219 |
| Independent ethical review of risks and benefits                   | 219 |
| Informed consent   | 220 |
| Recruitment of subjects  | 220 |
| Privacy and confidentiality  | 221 |
| Emerging ethical issues in neuroscience research                   | 222 |
| Research on vulnerable persons                                     | 222 |
| Are substance dependent people vulnerable persons?                 | 223 |
| Provocation studies  | 223 |
| Ethical issues in epidemiological research on substance dependence | 224 |
| Ethical issues in clinical trials of pharmacological treatments    |     |
| for substance dependence   | 225 |
| Trial design   | 225 |
|  |     |

## NEUROSCIENCE OF PSYCHOACTIVE SUBSTANCE USE AND DEPENDENCE

| ndex   | 251               |
|--|-------------------|
| Conclusion   | 248               |
| Implications for public health policy  | 247               |
| Ethical issues in the application of neuroscience findings                                       | 244               |
| Potential advances in policy, prevention and treatment   | 243               |
| Advances in the neuroscience of psychoactive substance use and dependence and their implications | 241               |
| Chapter 8. Conclusion and Implications for Public Health Policy Introduction                     | <b>241</b><br>241 |
| Summary and Conclusions  | 230               |
| Legally coerced treatment Summary and conclusions  | 232<br>235        |
| Access to treatment  | 232               |
| dependence   | 232               |
| Implications of neuroscience research for the treatment of substance                             |                   |
| dependence   | 231               |
| Implications of neuroscience research for models of substance                                    | 223               |
| Preventive use of drug immunotherapies   | 229               |
| dependence<br>Early intervention studies   | 227<br>227        |
| Trials of preventive pharmacological interventions for substance                                 | 00=               |
| Conflicts of interest  | 226               |
| Distributive justice   | 226               |